On June 17, 2016, Kent Emry, President and member of the board of directors of BioCorRx Inc. submitted his letter of resignation as president. Mr. Emry remains a member of the board. Mr. Emry's resignation as President did not arise as a result of any disagreement with the company.

Brady Granier is currently a member of the board and interim chief executive officer of the company. On June 17, 2016, the board appointed Mr. Granier president and removed the word Interim from Mr. Granier's title as chief executive officer. In connection with this appointment, Mr. Granier resigned as chief operating officer of the company.

Lourdes Felix is currently a member of the board and the chief financial officer of the company. On June 17, 2016, the board appointed Ms. Felix chief operating officer. Brady Granier was appointed a member of the board on March 4, 2013, chief operating officer on June 3, 2013, and interim chief executive officer on December 2, 2014.

In Mr. Granier's role as a senior executive of the company for the past 3 years he has spearheaded conceptualizing ideas, seizing opportunities, building operations, and leading new business development initiatives and ventures. Mr. Granier, along with the other executives, rebranded the company and restructured the model to position it for long term growth in the evolving addiction treatment space. During Mr. Granier's tenure in these roles, the company created a proprietary counseling program specific to the treatment of addiction using non-addictive naltrexone.

He also lead the acquisition of another naltrexone implant formulation to create more value for the company and he has also helped assemble what the company believes is a reputable team of advisors and consultants worldwide to assist the company in its future plans. Mr. Granier successfully maintained the company's viability along with the company's CFO by securing over $2 million in upfront license fees and royalty financing. In addition, he successfully negotiated the Financing Transaction.

Lourdes Felix was appointed chief financial officer on October 1, 2012 and a member of the board on March 4, 2013. Ms. Felix has over 20 years of combined experience in financial, accounting and general management in the private sector, public accounting and with publicly traded companies. Ms. Felix has extensive experience in mergers and acquisitions, due diligence, finance, investor relations and public reporting.

Ms. Felix is responsible for overseeing financial functions of the company including financial planning/analysis, accounting, forecasting, SEC compliance and reporting, tax, treasury and risk management. Ms. Felix played a major role, along with Mr. Granier in closing the financing transaction.